Skip to main content
. Author manuscript; available in PMC: 2020 Jul 21.
Published in final edited form as: J Mol Biol. 2017 Feb 21;429(7):1030–1044. doi: 10.1016/j.jmb.2017.02.010

Table 2.

Summary of immunocomplexes formed between Actoxumab and TcdA and their fragments as determined by SEC-MALLS

Antibody Antigen Molar ratio (Antibody:antigen) MW of complex (kDa) Putative stoichiometry (Antibody:antigen)
Actoxumab 146 1:0
Fab 47 1:0
TcdA 296 0:1
A1 100 0:1
Actoxumab TcdA 1:1 2141 5:4
5:1 2090 5:4
Actoxumab A1 1:5 359 1:2
1:1 394 2:1
2:1 653 3:2 or 4:1
5:1 1453 6:5, 7:4, or 8:3
Fab TcdA 1:5 324 1:1
1:1 358 1:1 or 2:1
5:1 389 2:1
10:1 393 2:1